BAXTER INTERNATIONAL INC acquired RECOTHROM and PREVELEAK products (from Mallinckrodt plc) for $184 million total consideration ($163 million upfront cash plus potential contingent payments), a transaction completed in March 2018, structured as all cash (with contingent consideration). The deal was a Asset purchase.
RECOTHROM and PREVELEAK products (from Mallinckrodt plc) operates in BioSurgery / hemostats and sealants, is based in Acquired from Mallinckrodt plc; products marketed primarily in the United States, had revenue of about Contributed $52 million of net sales to Baxter in 2018 (partial year). RECOTHROM Thrombin topical (Recombinant) is the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant is used in vascular reconstruction; both hemostat and sealant products were acquired from Mallinckrodt plc.
Adds complementary hemostat and sealant products to Baxter's regenerative medicine and biosurgery franchise.
Complementary hemostat and sealant products extending Baxter's BioSurgery franchise. Integrated into Baxter's BioSurgery / Advanced Surgery business
On March 16, 2018, Baxter acquired two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant) and PREVELEAK Surgical Sealant for total consideration of $184 million.Baxter FY2018 10-K, Acquisitions note
Advisory firms were not disclosed for this transaction.